Kraig Biocraft Laboratories Prepares for Challenge Testing of Disease Resistant Silkworm Lines

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) announced it will conduct challenge testing on two lines of immunity-enhanced silkworms to address significant losses in the silk industry caused by a widespread virus. Reportedly, 50% of silk production losses stem from this virus, affecting the economic viability of many producers. The company aims to license these transgenic silkworms globally, anticipating availability for commercial licensing post-successful testing. Kraig Labs continues to focus on the commercialization of eco-friendly recombinant spider silk.

Positive

• Development of immunity-enhanced silkworms aimed to significantly reduce production losses in the silk industry.
• Potential for licensing opportunities in a market projected to reach $21 billion by 2026.

Negative

• Dependence on successful challenge testing outcomes for future licensing opportunities.

Immunity enhanced silkworms provide licensing opportunities into the broader $14 B¹ silk industry

ANN ARBOR, Mich., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it is preparing to conduct challenge testing on two lines of immunity enhanced silkworms. These silkworm lines were developed by Kraig Labs to combat two of the biggest challenges facing the global silk production industry.

It has been reported that as much as 50% of all losses in silk production result from a single widespread virus. A 2020 paper cited that 75% of all interviewer silkworm raisers reported losses due to this disease. With no effective treatment, this virus results in countless millions of dollars of economic annually. Kraig Labs realized that technologies it was developing for other applications could be used to significantly reduce these losses in the broader silk industry. The Company has made rapid progress in the development of this new technology.

Specifically designed to target and combat this virus and other pathogens, these new transgenics developed by Kraig Labs, are now preparing to undergo challenge testing. These new disease-resistant lines of silkworms are intended for licensing into the global market for mundane silks to combat pathogenic viruses and fungi. The Company expects to make these lines of resilient silkworms available for commercial licensing shortly after the conclusion of successful challenge testing.

“We are very excited to begin challenge testing for these immunity enhanced silkworm lines,” said COO Jon Rice. “Our intention is to license this technology to silk produces all over the world. This program to produce licensable commercial lines of more robust silkworms is the perfect complement to our core focus, the commercialization of Kraig’s eco-friendly recombinant spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

___________________

¹ From New Analysis from Global Industry Analysts Reveals Steady Growth for Silk, with the Market to Reach $21 Billion Worldwide by 2026, read more at: https://www.prnewswire.com/news-releases/new-analysis-from-global-industry-analysts-reveals-steady-growth-for-silk-with-the-market-to-reach-21-billion-worldwide-by-2026-301377060.htm

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What is Kraig Biocraft Laboratories focusing on with its immunity-enhanced silkworms?

Kraig Biocraft Laboratories is preparing to conduct challenge testing on immunity-enhanced silkworms to combat significant production losses due to a widespread virus.

What market opportunities exist for Kraig Biocraft Laboratories' silkworm technology?

The company aims to license its developed silkworm technology, tapping into the broader silk industry projected to reach $21 billion by 2026.

What challenges does the global silk production industry face?

The silk production industry faces significant losses, with 50% caused by a virus that currently has no effective treatment.

When can we expect the immunity-enhanced silkworms to be commercially available?

Kraig Laboratories expects to make the disease-resistant silkworm lines available for commercial licensing shortly after successful challenge testing.